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CASE 
A 23-year-old man presented to an urgent care office with a 2-week history of rectal pain and scant 
rectal bleeding. In the few days leading up to his presentation, he also had a fever of 101° F (38.3° 
C), inguinal lymphadenopathy, and urinary retention. 
History 
About 6 months earlier, the patient had been treated for an unknown type of lymphoma and was 
now in remission. He is bisexual and has been in an exclusive relationship with another man for 
the past 6 months. Both men had been screened for sexually transmitted infections (STIs) before 
becoming intimate and all testing was negative. They used condoms irregularly, and the patient 
had engaged in receptive anal intercourse. Neither the patient nor his partner had a history of STIs, 
nor any lesions or symptoms concerning for STIs. 
Physical examination 
The patient had tender inguinal lymphadenopathy and exquisite rectal pain that precluded a digital 
rectal examination beyond the tip of the examiner’s finger. He had a small, healing anal fissure at 
the 6 o’clock location and no other lesions elsewhere on the body or anogenital region. 
Examination of the rest of the body (including the genitals) was unrevealing. 
Diagnostic testing 
Due to the patient’s lack of health insurance, the diagnostic workup was restricted to rectal testing 
for gonorrhea, chlamydia, and herpes simplex virus (HSV). Testing for HIV and syphilis was 
deferred so he could obtain this testing at a free clinic. Other tests that were considered but not 
done in the interest of cost reduction were a complete blood cell count and CT imaging of the 
pelvis to rule out an abscess or other abnormality. Urinalysis was considered but not done because 
the patient was unable to provide a spontaneous sample at the time of his visit. 
DIFFERENTIAL DIAGNOSIS 
• gonorrhea 
• chlamydia 
• proctitis caused by HSV 
• abscess of the colon 
OUTCOME 
The patient was treated empirically for gonorrhea and chlamydia with azithromycin (1 g orally) 
and ceftriaxone (250 mg IM), as well as HSV (acyclovir 400 mg orally every 8 hours). A colonic 
abscess was considered due to the anal fissure and history of anal intercourse; ciprofloxacin and 
metronidazole were prescribed empirically to cover this possibility. Two days later, polymerase 
chain reaction (PCR) testing isolated HSV type 2 from the rectal sample. The patient was 
diagnosed with proctitis caused by HSV type 2. Chlamydia and gonorrhea testing was negative. 
Acyclovir was continued, while ciprofloxacin and metronidazole were discontinued. Over the 10 
days of therapy, his symptoms gradually resolved. 
DISCUSSION 
HSV is a globally prevalent infection that exists as types 1 and 2. HSV type 1 typically is associated 
with nonsexual transmission during childhood and usually causes orolabial lesions; HSV type 2 is 
more commonly transmitted sexually and classically causes genital lesions. Both HSV types can 
cause symptoms in other areas (for example, oral HSV type 2) due to sexual behaviors. 
About 50 million Americans are infected with HSV type 2.1 Infected persons experience 
symptomatic flares throughout their lifetime, with the virus otherwise remaining dormant in the 
sacral ganglia. HSV infections also may be subclinical, so many infected patients are not 
diagnosed.2 Fewer than 20% of patients with HSV type 2 have recognized genital herpes.3 
Unbeknownst to many infected individuals, HSV type 2 can be sexually transmitted due to 
subclinical intermittent shedding of the virus via anterograde axonal transport to the skin and 
mucosal epithelia in the anogenital region.2 Studying a large cohort of HSV type 2-seropositive 
patients, Tronstein and colleagues found that on average, asymptomatic patients shed the virus on 
10% of days compared with symptomatic patients, who shed the virus on 20% of days.4 Although 
rates varied, the quantity of virus shed was similar between patient groups; therefore, transmission 
risk does not differ between asymptomatic and symptomatic patients during these subclinical 
genital shedding episodes.4 
Transmission occurs through direct contact with infected mucocutaneous surfaces or genital/oral 
secretions. Inoculation of the virus most commonly occurs at mucous membranes such as the 
orogenital regions or through small disruptions in the skin where epithelial cells and nerve endings 
become infected. Primary infection is followed by retrograde axonal transport to the sacral ganglia 
where the virus establishes its chronic infection. 
Proctitis, or inflammation located in but not confined to the rectum, is an uncommon manifestation 
of HSV type 2 (Figure 1). Acute proctitis among patients who have recently practiced receptive 
anal intercourse usually is sexually acquired.2 Typical pathogens for sexually transmitted proctitis 
include Chlamydia trachomatis, Neisseria gonorrhoeae, HSV, and Treponema pallidum.2 
Symptoms of HSV proctitis typically begin 1 to 3 weeks after exposure and include anorectal pain, 
tenesmus, difficulty in urination, sacral paresthesias, fever, and inguinal adenopathy.5 The classic 
vesicular lesions associated with HSV type 2 may not be visible on direct physical examination 
and can sometimes be indistinguishable from an anal fissure.5 
Modalities used to diagnose HSV (regardless of the anatomic site) include viral cultures, PCR, and 
herpes serology. PCR has a greater sensitivity than the traditional viral culture, and results can be 
available within hours.6 The CDC recommends additional testing for N. gonorrhoeae, 
C. trachomatis, and T. pallidum, as well as examination by anoscopy in patients suspected to have 
sexually transmitted proctitis.2 Mucosal friability or ulcerations, mucopurulent exudate, and 
external or perianal vesicles may be visualized through the anoscope in patients with HSV 
proctitis.5 Patients with severe rectal pain may not be able to tolerate such a procedure; consider 
general anesthesia or sedation if necessary.5 Alternatively, less-invasive testing may be performed 
as was done in this case. 
In a case of suspected sexually transmitted proctitis, empiric therapy should be initiated for N. 
gonorrhoeae and C. trachomatis before results of laboratory tests are available. If clinical 
suspicion of HSV infection is high, also start therapy for HSV. Treatment regimens vary with 
initial versus recurrent episodes of genital HSV, as well as suppressive therapy for patients with 
six or more outbreaks per year (Table 1). Men treated for sexually transmitted proctitis should 
abstain from sexual intercourse until they and their partner(s) have been treated and symptoms 
resolved. In addition to chlamydia, gonorrhea, and HSV, all patients with suspected sexually 
transmitted proctitis should be tested for HIV and syphilis, with repeat HIV testing in 3 months.2 
Because the anogenital lesions of sexually transmitted proctitis are associated with a 50% to 700% 
increase in HIV transmission, the diagnosis of sexually transmitted proctitis in an HIV-negative 
man who has sex with men should be considered a sentinel event necessitating education and risk-
reduction counseling.7 
Despite the high prevalence of HSV worldwide, routine screening is not recommended, and HSV 
testing is not part of general testing for STIs.2 Patients who participate in high-risk sexual behaviors 
should receive one-on-one counseling about preventing STIs and HIV. Additional counseling 
should involve education about HSV prevalence, chronicity, subclinical shedding, transmission, 
and typical/atypical presentations as that information may not be well understood in the general 
population. Because most patients who are seropositive for HSV type 2 are unaware of their 
infection status and screening is not recommended, patients must understand how to protect 
themselves. 
CONCLUSION 
As this case illustrates, the presentation of HSV infections can be variable and include neurologic 
abnormalities such as urinary retention. A high index of suspicion is essential for recognizing this 
very common infection in its less common manifestations. 
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TABLE 1. Oral treatment regimens for HSV infections2 
Therapy for initial genital HSV infections 
• Acyclovir 400 mg three times a day for 7 to 10 days 
• Acyclovir 200 mg fi ve times a day for 7 to 10 days 
• Valacyclovir 1 g twice a day for 7 to 10 days 
• Famciclovir 250 mg three times a day for 7 to 10 days 
Episodic therapy for recurrent genital HSV infections 
• Acyclovir 400 mg three times a day for 5 days 
• Acyclovir 800 mg twice a day for 5 days 
• Acyclovir 800 mg three times a day for 2 days 
• Valacyclovir 500 mg twice a day for 3 days 
• Valacyclovir 1 g once a day for 5 days 
• Famciclovir 125 mg twice a day for 5 days 
• Famciclovir 1 g twice a day for 1 day 
• Famciclovir 500 mg once, followed by 250 mg twice 
a day for 2 days 
Suppressive therapy for recurrent genital herpes 
• Acyclovir 400 mg twice a day 
• Valacyclovir 500 mg once a day 
• Valacyclovir 1 g once a day 
• Famciclovir 250 mg twice a day 
 
 
 
 
 
 
 
